APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vimentin Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vimentin Antibody Market Outlook and Growth Opportunities 2026

19 December 2025208 pages

Choose your research edition.

Industry ResearchVimentin Antibody Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Vimentin Antibody Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Vimentin Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vimentin Antibody Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Vimentin Antibody Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Vimentin Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vimentin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vimentin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vimentin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vimentin Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vimentin Antibody market include Merck, Boster Biological Technology, United States Biological, Synaptic, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents and Miltenyi Biotec, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vimentin Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vimentin Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vimentin Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vimentin Antibody market.

Vimentin Antibody Segment by Company

Merck

Boster Biological Technology

United States Biological

Synaptic

Santa Cruz Biotechnology

Proteintech

ProSci

NSJ Bioreagents

Miltenyi Biotec

GeneTex

FineTest

EXBIO

Everest Biotech

Bio-Rad

BioLegend

Atlas Antibodies

Vimentin Antibody Segment by Type

Polyclonal

Monoclonal

Vimentin Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Enzyme Linked Immunosorbent Assay

Flow Cytometry

Western Blot

Others

Vimentin Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vimentin Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vimentin Antibody key companies, revenue, market share, and recent developments.

3. To split the Vimentin Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vimentin Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vimentin Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Vimentin Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vimentin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vimentin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vimentin Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vimentin Antibody industry.

Chapter 3: Detailed analysis of Vimentin Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vimentin Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vimentin Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vimentin Antibody Industry Trends Table 2. Vimentin Antibody Industry Drivers Table 3. Vimentin Antibody Industry Opportunities and Challenges Table 4. Vimentin Antibody Industry Restraints Table 5. Global Vimentin Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vimentin Antibody Revenue Share by Company (2021-2026) Table 7. Global Vimentin Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vimentin Antibody Key Company Manufacturing Base & Headquarters Table 9. Global Vimentin Antibody Company, Product Type & Application Table 10. Global Vimentin Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vimentin Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global Vimentin Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Vimentin Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Vimentin Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Vimentin Antibody Sales Value Share by Type (2021-2026) Table 20. Global Vimentin Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Paraffin Table 22. Significant Companies of Immunohistochemistry Frozen Table 23. Significant Companies of Enzyme Linked Immunosorbent Assay Table 24. Significant Companies of Flow Cytometry Table 25. Significant Companies of Western Blot Table 26. Significant Companies of Others Table 27. Global Vimentin Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Vimentin Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Vimentin Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Vimentin Antibody Sales Value Share by Application (2021-2026) Table 31. Global Vimentin Antibody Sales Value Share by Application (2027-2032) Table 32. Global Vimentin Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Vimentin Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Vimentin Antibody Sales Value Share by Region (2021-2026) Table 35. Global Vimentin Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Vimentin Antibody Sales Value Share by Region (2027-2032) Table 37. Global Vimentin Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vimentin Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Vimentin Antibody Sales Value Market Share by Country (2021-2026) Table 40. Global Vimentin Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Vimentin Antibody Sales Value Market Share by Country (2027-2032) Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Merck Vimentin Antibody Product Portfolio Table 46. Merck Recent Development Table 47. Boster Biological Technology Company Information Table 48. Boster Biological Technology Business Overview Table 49. Boster Biological Technology Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Boster Biological Technology Vimentin Antibody Product Portfolio Table 51. Boster Biological Technology Recent Development Table 52. United States Biological Company Information Table 53. United States Biological Business Overview Table 54. United States Biological Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. United States Biological Vimentin Antibody Product Portfolio Table 56. United States Biological Recent Development Table 57. Synaptic Company Information Table 58. Synaptic Business Overview Table 59. Synaptic Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Synaptic Vimentin Antibody Product Portfolio Table 61. Synaptic Recent Development Table 62. Santa Cruz Biotechnology Company Information Table 63. Santa Cruz Biotechnology Business Overview Table 64. Santa Cruz Biotechnology Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Santa Cruz Biotechnology Vimentin Antibody Product Portfolio Table 66. Santa Cruz Biotechnology Recent Development Table 67. Proteintech Company Information Table 68. Proteintech Business Overview Table 69. Proteintech Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Proteintech Vimentin Antibody Product Portfolio Table 71. Proteintech Recent Development Table 72. ProSci Company Information Table 73. ProSci Business Overview Table 74. ProSci Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. ProSci Vimentin Antibody Product Portfolio Table 76. ProSci Recent Development Table 77. NSJ Bioreagents Company Information Table 78. NSJ Bioreagents Business Overview Table 79. NSJ Bioreagents Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. NSJ Bioreagents Vimentin Antibody Product Portfolio Table 81. NSJ Bioreagents Recent Development Table 82. Miltenyi Biotec Company Information Table 83. Miltenyi Biotec Business Overview Table 84. Miltenyi Biotec Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Miltenyi Biotec Vimentin Antibody Product Portfolio Table 86. Miltenyi Biotec Recent Development Table 87. GeneTex Company Information Table 88. GeneTex Business Overview Table 89. GeneTex Vimentin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. GeneTex Vimentin Antibody Product Portfolio Table 91. GeneTex Recent Development Table 92. FineTest Company Information Table 93. FineTest Business Overview Table 94. FineTest Vimentin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. FineTest Vimentin Antibody Product Portfolio Table 96. FineTest Recent Development Table 97. EXBIO Company Information Table 98. EXBIO Business Overview Table 99. EXBIO Vimentin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. EXBIO Vimentin Antibody Product Portfolio Table 101. EXBIO Recent Development Table 102. Everest Biotech Company Information Table 103. Everest Biotech Business Overview Table 104. Everest Biotech Vimentin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Everest Biotech Vimentin Antibody Product Portfolio Table 106. Everest Biotech Recent Development Table 107. Bio-Rad Company Information Table 108. Bio-Rad Business Overview Table 109. Bio-Rad Vimentin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Bio-Rad Vimentin Antibody Product Portfolio Table 111. Bio-Rad Recent Development Table 112. BioLegend Company Information Table 113. BioLegend Business Overview Table 114. BioLegend Vimentin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. BioLegend Vimentin Antibody Product Portfolio Table 116. BioLegend Recent Development Table 117. Atlas Antibodies Company Information Table 118. Atlas Antibodies Business Overview Table 119. Atlas Antibodies Vimentin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Atlas Antibodies Vimentin Antibody Product Portfolio Table 121. Atlas Antibodies Recent Development Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Vimentin Antibody Product Image Figure 2. Global Vimentin Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vimentin Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Vimentin Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global Vimentin Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Vimentin Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Vimentin Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Paraffin Image Figure 13. Immunohistochemistry Frozen Image Figure 14. Enzyme Linked Immunosorbent Assay Image Figure 15. Flow Cytometry Image Figure 16. Western Blot Image Figure 17. Others Image Figure 18. Global Vimentin Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Vimentin Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Vimentin Antibody Sales Value Share by Application (2021-2032) Figure 21. Global Vimentin Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Vimentin Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Vimentin Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. North America Vimentin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Vimentin Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Vimentin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Vimentin Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Vimentin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Vimentin Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. South America Vimentin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Vimentin Antibody Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Vimentin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Vimentin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Vimentin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Vimentin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Enzyme Linked Immunosorbent Assay
  • Flow Cytometry
  • Western Blot
  • Others
Companies covered
  • Merck
  • Boster Biological Technology
  • United States Biological
  • Synaptic
  • Santa Cruz Biotechnology
  • Proteintech
  • ProSci
  • NSJ Bioreagents
  • Miltenyi Biotec
  • GeneTex
  • FineTest
  • EXBIO
  • Everest Biotech
  • Bio-Rad
  • BioLegend
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vimentin Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vimentin Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vimentin Antibody Market Dynamics
  1. 2.1 Vimentin Antibody Industry Trends
  2. 2.2 Vimentin Antibody Industry Drivers
  3. 2.3 Vimentin Antibody Industry Opportunities and Challenges
  4. 2.4 Vimentin Antibody Industry Restraints
3 Vimentin Antibody Market by Company
  1. 3.1 Global Vimentin Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Vimentin Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Vimentin Antibody Company Ranking (2024-2026)
  4. 3.4 Global Vimentin Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global Vimentin Antibody Company Product Type and Application
  6. 3.6 Global Vimentin Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vimentin Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vimentin Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vimentin Antibody Market by Type
  1. 4.1 Vimentin Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global Vimentin Antibody Sales Value by Type
  5. 4.2.1 Global Vimentin Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vimentin Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global Vimentin Antibody Sales Value Share by Type (2021-2032)
5 Vimentin Antibody Market by Application
  1. 5.1 Vimentin Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Paraffin
  3. 5.1.2 Immunohistochemistry Frozen
  4. 5.1.3 Enzyme Linked Immunosorbent Assay
  5. 5.1.4 Flow Cytometry
  6. 5.1.5 Western Blot
  7. 5.1.6 Others
  8. 5.2 Global Vimentin Antibody Sales Value by Application
  9. 5.2.1 Global Vimentin Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Vimentin Antibody Sales Value by Application (2021-2032)
  11. 5.2.3 Global Vimentin Antibody Sales Value Share by Application (2021-2032)
6 Vimentin Antibody Regional Value Analysis
  1. 6.1 Global Vimentin Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vimentin Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vimentin Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vimentin Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vimentin Antibody Sales Value (2021-2032)
  7. 6.3.2 North America Vimentin Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vimentin Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe Vimentin Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vimentin Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vimentin Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vimentin Antibody Sales Value (2021-2032)
  16. 6.6.2 South America Vimentin Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vimentin Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vimentin Antibody Sales Value Share by Country, 2025 VS 2032
7 Vimentin Antibody Country-level Value Analysis
  1. 7.1 Global Vimentin Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vimentin Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vimentin Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vimentin Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vimentin Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vimentin Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vimentin Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vimentin Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vimentin Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vimentin Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vimentin Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vimentin Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vimentin Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vimentin Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vimentin Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vimentin Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vimentin Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vimentin Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vimentin Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vimentin Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vimentin Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vimentin Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vimentin Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vimentin Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vimentin Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vimentin Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vimentin Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vimentin Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vimentin Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vimentin Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vimentin Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vimentin Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vimentin Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vimentin Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Vimentin Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Vimentin Antibody Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Boster Biological Technology
  8. 8.2.1 Boster Biological Technology Company Information
  9. 8.2.2 Boster Biological Technology Business Overview
  10. 8.2.3 Boster Biological Technology Vimentin Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boster Biological Technology Vimentin Antibody Product Portfolio
  12. 8.2.5 Boster Biological Technology Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological Vimentin Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological Vimentin Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Synaptic
  20. 8.4.1 Synaptic Company Information
  21. 8.4.2 Synaptic Business Overview
  22. 8.4.3 Synaptic Vimentin Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Synaptic Vimentin Antibody Product Portfolio
  24. 8.4.5 Synaptic Recent Developments
  25. 8.5 Santa Cruz Biotechnology
  26. 8.5.1 Santa Cruz Biotechnology Company Information
  27. 8.5.2 Santa Cruz Biotechnology Business Overview
  28. 8.5.3 Santa Cruz Biotechnology Vimentin Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Santa Cruz Biotechnology Vimentin Antibody Product Portfolio
  30. 8.5.5 Santa Cruz Biotechnology Recent Developments
  31. 8.6 Proteintech
  32. 8.6.1 Proteintech Company Information
  33. 8.6.2 Proteintech Business Overview
  34. 8.6.3 Proteintech Vimentin Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Proteintech Vimentin Antibody Product Portfolio
  36. 8.6.5 Proteintech Recent Developments
  37. 8.7 ProSci
  38. 8.7.1 ProSci Company Information
  39. 8.7.2 ProSci Business Overview
  40. 8.7.3 ProSci Vimentin Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ProSci Vimentin Antibody Product Portfolio
  42. 8.7.5 ProSci Recent Developments
  43. 8.8 NSJ Bioreagents
  44. 8.8.1 NSJ Bioreagents Company Information
  45. 8.8.2 NSJ Bioreagents Business Overview
  46. 8.8.3 NSJ Bioreagents Vimentin Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NSJ Bioreagents Vimentin Antibody Product Portfolio
  48. 8.8.5 NSJ Bioreagents Recent Developments
  49. 8.9 Miltenyi Biotec
  50. 8.9.1 Miltenyi Biotec Company Information
  51. 8.9.2 Miltenyi Biotec Business Overview
  52. 8.9.3 Miltenyi Biotec Vimentin Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Miltenyi Biotec Vimentin Antibody Product Portfolio
  54. 8.9.5 Miltenyi Biotec Recent Developments
  55. 8.10 GeneTex
  56. 8.10.1 GeneTex Company Information
  57. 8.10.2 GeneTex Business Overview
  58. 8.10.3 GeneTex Vimentin Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GeneTex Vimentin Antibody Product Portfolio
  60. 8.10.5 GeneTex Recent Developments
  61. 8.11 FineTest
  62. 8.11.1 FineTest Company Information
  63. 8.11.2 FineTest Business Overview
  64. 8.11.3 FineTest Vimentin Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 FineTest Vimentin Antibody Product Portfolio
  66. 8.11.5 FineTest Recent Developments
  67. 8.12 EXBIO
  68. 8.12.1 EXBIO Company Information
  69. 8.12.2 EXBIO Business Overview
  70. 8.12.3 EXBIO Vimentin Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 EXBIO Vimentin Antibody Product Portfolio
  72. 8.12.5 EXBIO Recent Developments
  73. 8.13 Everest Biotech
  74. 8.13.1 Everest Biotech Company Information
  75. 8.13.2 Everest Biotech Business Overview
  76. 8.13.3 Everest Biotech Vimentin Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Everest Biotech Vimentin Antibody Product Portfolio
  78. 8.13.5 Everest Biotech Recent Developments
  79. 8.14 Bio-Rad
  80. 8.14.1 Bio-Rad Company Information
  81. 8.14.2 Bio-Rad Business Overview
  82. 8.14.3 Bio-Rad Vimentin Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bio-Rad Vimentin Antibody Product Portfolio
  84. 8.14.5 Bio-Rad Recent Developments
  85. 8.15 BioLegend
  86. 8.15.1 BioLegend Company Information
  87. 8.15.2 BioLegend Business Overview
  88. 8.15.3 BioLegend Vimentin Antibody Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BioLegend Vimentin Antibody Product Portfolio
  90. 8.15.5 BioLegend Recent Developments
  91. 8.16 Atlas Antibodies
  92. 8.16.1 Atlas Antibodies Company Information
  93. 8.16.2 Atlas Antibodies Business Overview
  94. 8.16.3 Atlas Antibodies Vimentin Antibody Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Atlas Antibodies Vimentin Antibody Product Portfolio
  96. 8.16.5 Atlas Antibodies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst